Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca

By Bonnie Eslinger · May 17, 2024, 8:26 PM EDT

A Delaware federal jury on Friday said that AstraZeneca Pharmaceuticals LP should pay $107.5 million in royalty damages for infringing a Pfizer-brand cancer treatment patent, although a final decision won't be issued...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP et al

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

September 22, 2021

Recent Articles By Bonnie

March 22, 2024
Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
March 11, 2024
Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug
March 08, 2024
Trump 'An Existential Threat' To Rule Of Law, Attys Warn
January 22, 2024
HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case
January 08, 2024
Teva, Israeli Investors End Investor Suit Over Opioid Scandal
January 05, 2024
9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
January 03, 2024
ACTS Retirement Data Breach Suit Settlement Gets Initial OK
December 20, 2023
Calif. County Workers Near Cert. In Vaccine Exemption Suit
December 07, 2023
Bankrupt Drug Treatment Center Takes Cigna Row To 9th Circ.
November 03, 2023
AI Will 'Revolutionize' Class Action Payouts, Judge Says